Abstract:Reflux esophagitis, a treatment for gastric ulcers known as Ilaprazole (Ila), is not stable during storage and handling at room temperature, requiring storage at 5 degrees Celsius. In this study, to address these issues with Ila, coformers rich in oxygen (O) and hydroxyl (OH) groups capable of forming hydrogen bonds with were selected. These coformers included Xylitol (Xyl), Meglumine (Meg), Nicotinic acid (Nic), L-Aspartic acid (Asp), and L-Glutamic acid (Glu). A 1:1 physical mixture of Ila and each coformer was prepared, and the potential for cocrystal formation was predicted using differential scanning calorimetry (DSC) screening. The results indicated the potential for cocrystal formation in the Ila/Xyl physical mixture. Subsequently, Ila and Xyl were mixed in ethyl acetate (EA) in a 1:1 ratio, and after 28 h of slurry, the formation of Ila/Xyl cocrystal was confirmed through solid-state CP/MAS 13C NMR spectrum analysis, showing intermolecular hydrogen bonding and conformational changes. Furthermore, the 1:1 ratio of Ila/Xyl cocrystal was confirmed through solution-state NMR (1H, 13C, and 2D) molecular structure analysis. To assess the stability of Ila/Xyl cocrystal at room temperature, it was stored and compared with Ila at 25 ± 2 °C and relative humidity (RH) of 65 ± 5% over three months. The results showed that the purity of Ila/Xyl cocrystal remained at 99.8% from the initial purity of 99.75% over the three months, while Ila was predicted to decrease from an initial 99.8% purity to 90% after three months. Additionally, at 25 ± 2 °C and RH 65 ± 5%, a specific impurity B in Ila/Xyl cocrystal was observed to be 0.03% over three months, whereas Ila was predicted to increase from an initial 0.032% to 2.28% after three months. To evaluate the dissolution rate of Ila/Xyl cocrystal, a formulation was prepared and compared with Ila at pH 10, with a dosage equivalent to 10 mg of Ila. The results showed that Ila/Xyl cocrystal reached 55% within 15 min and 100% within 45 min, while Ila was predicted to reach 32% at 15 min and 100% only after 60 min. However, overall, the Ila/Xyl cocrystal showed results equivalent to or exceeding the dissolution rate of Ila. Therefore, it is predicted that the Ila/Xyl cocrystal will maximize its effectiveness as a more convenient crystal structure for formulation development, allowing storage and preservation at room temperature without the need for the problematic 5 °C refrigeration during ambient conditions and storage, addressing the issues associated with Ila.

Using Dissolution and Pharmacokinetics Studies of Crystal Form to Optimize the Original Iloperidone

Syntheses and Pharmacokinetics Properties of an Iloperidone Pharmaceutical Cocrystal

Increasing the Dissolution Rate of A Low-Solubility Drug Through A Crystalline-Amorphous Transition: A Case Study with Indomethicin

Solid amorphous formulations for enhancing solubility and inhibiting Erlotinib crystallization during gastric-to-intestinal transfer

Dissolution and pharmacokinetic properties of two paliperidone cocrystals with 4-hydroxybenzoic and 4-aminobenzoic acid

Polymorphs and pharmacokinetics of an antipsychotic drug candidate

Investigation of the Storage and Stability as Well as the Dissolution Rate of Novel Ilaprazole/Xylitol Cocrystal

Studies on the Crystal Forms of Istradefylline: Structure, Solubility, and Dissolution Profile

Bioavailability-Enhancing Cocrystals: Screening, In Vivo Predictive Dissolution, and Supersaturation Maintenance

Synthesis and structural characterization of two novel olanzapine cocrystals with decreased or enhanced dissolution rate

Using the Cocrystal Approach as a Promising Drug Delivery System to Enhance the Dissolution and Bioavailability of Formononetin Using an Imidazole Coformer

Systematic Approach in the Development of Chitosan Functionalized Iloperidone Nanoemulsions for Transnasal Delivery, In Vitro and In Vivo Studies

Influence of different polymers on crystallization tendency and dissolution behavior of cilnidipine in solid dispersions.

Solubility and Permeability Improvement of Allopurinol by Cocrystallization

Optimisation of Pharmaceutical Cocrystal Dissolution Performance through a Synergistic Precipitation Inhibition

Preparation, Characterization and in Vivo Evaluation of Pharmacological Activity of Different Crystal Forms of Ibuprofen

High-Throughput Excipient Discovery Enables Oral Delivery of Poorly Soluble Pharmaceuticals

Combination of co-crystal and nanocrystal techniques to improve the solubility and dissolution rate of poorly soluble drugs

Crystallization Kinetics and Molecular Dynamics of Binary Coamorphous Systems of Nimesulide and Profen Analogs

Oral Bioavailability Enhancement of Β-Lapachone, a Poorly Soluble Fast Crystallizer, by Cocrystal, Amorphous Solid Dispersion, and Crystalline Solid Dispersion.

Sustainable preparation of spherical particles of novel carbamazepine-hesperetin cocrystal via different crystallization strategies: From mechanism to application